DAPT Calculator
Estimate your daptcalculator with our free cardiovascular system calculator. See reference ranges, risk factors, and next-step guidance.
Calculator
Adjust values & calculateStandard DAPT duration (12 months or shorter) is favored. The bleeding risk of prolonged DAPT likely outweighs the ischemic benefit. Consider discontinuing P2Y12 inhibitor after 12 months.
Formula
Age provides -2 (75+), -1 (65-74), or 0 (<65) points. Other factors add +1 or +2 points each. Total ranges from -2 to 10. Score of 2 or higher favors extended 30-month DAPT; below 2 favors standard 12-month duration.
Last reviewed: January 2026
Worked Examples
Example 1: Score Favoring Prolonged DAPT
Example 2: Score Favoring Standard Duration
Background & Theory
The DAPT Calculator applies the following established principles and formulas. Health and medicine calculators are grounded in validated physiological measurement methods established through decades of clinical research. Body Mass Index, or BMI, is calculated by dividing weight in kilograms by height in meters squared (kg/m²), a formula originating from Adolphe Quetelet's 19th-century statistical work and later codified by the WHO into standard classifications: underweight below 18.5, normal weight 18.5 to 24.9, overweight 25 to 29.9, and obese at 30 and above. Basal Metabolic Rate quantifies the minimum energy required to sustain life at rest. The Mifflin-St Jeor equation, published in 1990 and widely regarded as the most accurate for most adults, calculates BMR as (10 × weight in kg) + (6.25 × height in cm) − (5 × age) ± sex adjustment. The older Harris-Benedict equations, revised in 1984 by Roza and Shizgal, remain in common use. Total Daily Energy Expenditure is derived by multiplying BMR by a physical activity factor ranging from 1.2 for sedentary individuals to 1.9 for extremely active ones, following the methodology validated by doubly labeled water studies. Body fat percentage can be estimated without laboratory equipment using the U.S. Navy circumference method, which uses neck, waist, and hip measurements, or via BMI-derived equations adjusted for age and sex. The Jackson-Pollock skinfold method offers higher precision with calipers. Blood pressure classification, according to the American College of Cardiology and the 2017 ACC/AHA guidelines, defines normal as below 120/80 mmHg, elevated as 120 to 129 systolic, and hypertension stage 1 as 130 to 139 systolic or 80 to 89 diastolic. Target heart rate zones for aerobic exercise are derived from maximum heart rate estimates, most commonly using the formula 220 minus age in years, with moderate-intensity training typically defined as 50 to 70 percent of maximum heart rate and vigorous intensity at 70 to 85 percent, consistent with CDC and American Heart Association guidelines. These thresholds guide safe and effective cardiovascular conditioning.
History
The history behind the DAPT Calculator traces back through the following developments. The history of health measurement stretches back to ancient Greece, where Hippocrates around 400 BCE laid the foundation for observational medicine by systematically recording patient symptoms, diet, and environment. His humoral theory, though scientifically superseded, established the principle that the body operates as an interconnected system subject to measurable imbalance. The transformation toward modern medicine accelerated in the 19th century. Louis Pasteur and Robert Koch developed germ theory in the 1860s and 1870s, identifying microorganisms as disease agents and enabling targeted interventions. Florence Nightingale, working during the Crimean War in the 1850s, introduced statistical analysis to nursing practice, demonstrating through data visualization that sanitation reduced mortality. Her work is foundational to evidence-based health measurement. The discovery of vitamins in the early 20th century, beginning with Casimir Funk's coinage of the term in 1912 and culminating in the isolation of vitamins A through K, created the field of nutritional science and gave rise to dietary reference intake frameworks. The World Health Organization, founded in 1948, subsequently established global standards for health metrics, disease classification through the International Classification of Diseases, and recommended daily allowances. The BMI as a clinical screening tool gained traction in the 1970s through Ancel Keys' large-scale epidemiological work, which validated Quetelet's index as a population-level obesity indicator. Through the 1980s and 1990s, the Framingham Heart Study produced landmark data linking cholesterol, blood pressure, and lifestyle factors to cardiovascular disease risk, directly shaping the numeric thresholds still used in health calculators. The evidence-based medicine movement, formalized by Gordon Guyatt and colleagues at McMaster University in the early 1990s, demanded that all health recommendations derive from systematically graded clinical evidence. The digital health era beginning in the 2000s brought these formulas to consumer devices, wearable sensors, and smartphone applications, expanding access to health self-monitoring on a global scale and enabling population-level data collection that continues to refine clinical reference ranges.
Frequently Asked Questions
Sources & References
- 1Yeh RW, et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy. JAMA. 2016;315(16):1735-1749.
- 2Mauri L, et al. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents (DAPT Study). N Engl J Med. 2014;371(23):2155-2166.
- 3Levine GN, et al. 2016 ACC/AHA Focused Update on Duration of DAPT. Circulation. 2016;134(10):e123-e155.
Formula
DAPT Score = Age points + Smoking + Diabetes + MI + Prior PCI + Stent size + Stent type + CHF + Vein graft
Age provides -2 (75+), -1 (65-74), or 0 (<65) points. Other factors add +1 or +2 points each. Total ranges from -2 to 10. Score of 2 or higher favors extended 30-month DAPT; below 2 favors standard 12-month duration.
Worked Examples
Example 1: Score Favoring Prolonged DAPT
Problem: A 58-year-old male smoker with diabetes who presented with MI, received a 2.5mm DES. No prior PCI, no CHF, no vein graft. Calculate DAPT score at 12 months.
Solution: Age <65: 0 points\nCigarette smoking: +1\nDiabetes: +1\nMI at presentation: +1\nPrior PCI/MI: 0\nStent diameter <3mm: +1\nPaclitaxel stent: 0\nCHF/LVEF <30%: 0\nVein graft: 0\nTotal DAPT Score = 4
Result: DAPT Score: 4 (>=2, prolonged DAPT for 30 months is favored)
Example 2: Score Favoring Standard Duration
Problem: A 76-year-old non-smoking, non-diabetic patient who had elective PCI with a 3.5mm DES for stable angina. No prior PCI, no CHF, no vein graft.
Solution: Age >=75: -2 points\nCigarette smoking: 0\nDiabetes: 0\nMI at presentation: 0 (stable angina)\nPrior PCI/MI: 0\nStent diameter <3mm: 0 (3.5mm stent)\nPaclitaxel stent: 0\nCHF/LVEF <30%: 0\nVein graft: 0\nTotal DAPT Score = -2
Result: DAPT Score: -2 (<2, standard 12-month DAPT duration is favored)
Frequently Asked Questions
What is the DAPT score and what does it determine?
The DAPT (Dual Antiplatelet Therapy) score is a clinical decision-support tool developed to help determine the optimal duration of dual antiplatelet therapy after coronary stent implantation. The score was derived from the landmark DAPT Study, which randomized over 11,000 patients who had tolerated 12 months of DAPT without events to either continued thienopyridine therapy or placebo for an additional 18 months. The score integrates nine clinical and procedural variables to produce a value ranging from -2 to 10. A score of 2 or higher identifies patients who derive greater ischemic benefit from prolonged DAPT (30 months) relative to the increased bleeding risk, while a score below 2 suggests the bleeding risk of extended therapy outweighs the ischemic benefit. The tool helps personalize treatment duration rather than applying a one-size-fits-all approach.
How is the DAPT score calculated and what are its components?
The DAPT score assigns points based on nine clinical and procedural factors assessed at the time of the decision about extending DAPT beyond 12 months. Age provides negative points: age 75 or older gets -2, age 65-74 gets -1, and age under 65 gets 0 points. Positive points are assigned for current cigarette smoking (+1), diabetes mellitus (+1), MI at presentation (+1), prior PCI or prior MI (+1), stent diameter less than 3 mm (+1), paclitaxel-eluting stent (+1), CHF or LVEF less than 30 percent (+2), and saphenous vein graft PCI (+2). The total score ranges from -2 to 10. The scoring reflects the balance between ischemic risk factors (which favor prolonged therapy) and bleeding risk factors (primarily age, which favors shorter therapy).
When should the DAPT score be applied in clinical practice?
The DAPT score should be applied at or around the 12-month mark after coronary stent implantation to guide the decision about whether to continue or discontinue the P2Y12 inhibitor component of dual antiplatelet therapy. Critically, the score is only valid for patients who have completed 12 months of DAPT without experiencing a major bleeding event, myocardial infarction, or stroke during that period. Patients who have complications during the initial 12 months require individualized assessment rather than score-based guidance. The score is most applicable to patients who received drug-eluting stents, as bare-metal stents typically require only 1 month of DAPT. Additionally, the score was developed primarily for patients on clopidogrel and may not directly apply to those on prasugrel or ticagrelor, though the risk factor principles remain relevant.
What are the risks of stent thrombosis if DAPT is stopped too early?
Stent thrombosis is among the most feared complications after coronary intervention, occurring when a blood clot forms within the stent and abruptly occludes the coronary artery. It presents as acute myocardial infarction with mortality rates of 20 to 45 percent per event. Stent thrombosis is classified by timing: acute (within 24 hours), subacute (1-30 days), late (30 days to 1 year), and very late (beyond 1 year). Premature discontinuation of DAPT is the strongest predictor of stent thrombosis, with risk increasing 90-fold in the first 30 days and remaining elevated for months. First-generation drug-eluting stents had higher rates of very late stent thrombosis (0.4-0.6 percent per year) compared to newer-generation stents (0.1-0.2 percent per year), which have thinner struts and more biocompatible polymers. The improved safety profile of contemporary stents has enabled consideration of shorter DAPT durations in selected low-risk patients.
How do newer P2Y12 inhibitors affect the DAPT duration decision?
Prasugrel and ticagrelor are more potent P2Y12 inhibitors than clopidogrel, providing faster onset, greater platelet inhibition, and more consistent pharmacological effect. The TRITON-TIMI 38 trial showed prasugrel reduced ischemic events by 19 percent compared to clopidogrel but increased major bleeding by 32 percent, with particular harm in patients over 75, those with prior stroke, and those weighing less than 60 kg. The PLATO trial demonstrated ticagrelor reduced cardiovascular death by 21 percent compared to clopidogrel with modestly increased non-CABG bleeding. When considering DAPT duration with these agents, their greater antiplatelet potency means both the ischemic protection and bleeding risk per unit time are amplified compared to clopidogrel. Some clinicians use the DAPT score as a framework but apply lower thresholds for extended duration or consider de-escalation strategies switching from potent agents to clopidogrel after an initial high-risk period.
What bleeding complications can occur with prolonged DAPT?
Prolonged dual antiplatelet therapy increases the risk of various bleeding complications through sustained inhibition of platelet aggregation. Gastrointestinal bleeding is the most common major bleeding site, occurring in approximately 1 to 2 percent of patients per year on DAPT, often from peptic ulcers, erosive gastritis, or lower GI sources. Intracranial hemorrhage, though rare at 0.1 to 0.3 percent annually, is the most devastating complication with high mortality and morbidity. Other bleeding manifestations include epistaxis, hematuria, bruising, and prolonged bleeding from minor wounds. The DAPT trial showed that extending therapy from 12 to 30 months increased GUSTO moderate or severe bleeding from 1.6 to 2.5 percent. Proton pump inhibitor co-prescription reduces GI bleeding risk significantly and is recommended for all patients on DAPT with risk factors including age over 65, concurrent anticoagulation, corticosteroid use, or prior GI bleeding.
References
- Yeh RW, et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy. JAMA. 2016;315(16):1735-1749.
- Mauri L, et al. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents (DAPT Study). N Engl J Med. 2014;371(23):2155-2166.
- Levine GN, et al. 2016 ACC/AHA Focused Update on Duration of DAPT. Circulation. 2016;134(10):e123-e155.
Reviewed by Rahul Singh, Health & Wellness Specialist · Editorial policy